ATE527998T1 - Illudin-analoga als krebsmittel - Google Patents

Illudin-analoga als krebsmittel

Info

Publication number
ATE527998T1
ATE527998T1 AT06800754T AT06800754T ATE527998T1 AT E527998 T1 ATE527998 T1 AT E527998T1 AT 06800754 T AT06800754 T AT 06800754T AT 06800754 T AT06800754 T AT 06800754T AT E527998 T1 ATE527998 T1 AT E527998T1
Authority
AT
Austria
Prior art keywords
analogas
illudin
cancer medicine
tumors
vivo
Prior art date
Application number
AT06800754T
Other languages
German (de)
English (en)
Inventor
Trevor C Mcmorris
Michael J Kelner
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE527998T1 publication Critical patent/ATE527998T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/95—Spiro compounds containing "not free" spiro atoms
    • C07C2603/96—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members
    • C07C2603/97—Spiro compounds containing "not free" spiro atoms containing at least one ring with less than six members containing five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06800754T 2005-08-03 2006-08-03 Illudin-analoga als krebsmittel ATE527998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70501705P 2005-08-03 2005-08-03
PCT/US2006/030439 WO2007019308A2 (en) 2005-08-03 2006-08-03 Illudin analogs useful as anticancer agents

Publications (1)

Publication Number Publication Date
ATE527998T1 true ATE527998T1 (de) 2011-10-15

Family

ID=37727922

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06800754T ATE527998T1 (de) 2005-08-03 2006-08-03 Illudin-analoga als krebsmittel

Country Status (5)

Country Link
US (1) US7655695B2 (https=)
EP (1) EP1909783B1 (https=)
JP (1) JP4989648B2 (https=)
AT (1) ATE527998T1 (https=)
WO (1) WO2007019308A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932553A (en) * 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US10285955B2 (en) 2014-04-10 2019-05-14 Af Chemicals, Llc Affinity medicant conjugate
US11135182B2 (en) 2014-04-10 2021-10-05 Af Chemicals, Llc Affinity medicant conjugates
WO2015157578A2 (en) 2014-04-10 2015-10-15 Af Chemicals, Llc Affinity medicant conjugates
JP7489966B2 (ja) * 2018-09-04 2024-05-24 ランタン ファルマ インコーポレイテッド イルジン類似体、それらの使用、およびそれらを合成する方法
AU2019361781A1 (en) * 2018-10-14 2021-06-03 Lantern Pharma Inc. Methods for the treatment of solid tumor cancers using illudins and biomarkers
EP3667323B1 (en) 2018-12-11 2024-11-13 AF Chemical LLC Methods, compositions and devices for treating cancer with illudofulvenes
US11591295B2 (en) 2019-11-25 2023-02-28 Af Chemicals Llc Affinity illudofulvene conjugates
BR112022020595A2 (pt) * 2020-04-10 2023-01-17 Lantern Pharma Inc Métodos hidroxiureametil-acilfulveno para tratamento de câncer do cérebro ou câncer do snc.
EP4146181A4 (en) * 2020-05-08 2024-10-09 Lantern Pharma Inc. METHODS FOR TREATING PANCREATIC CANCER
WO2022147072A1 (en) * 2020-12-29 2022-07-07 Lantern Pharma Inc. Method for treating rhabdoid tumors
CN116847834A (zh) * 2021-01-08 2023-10-03 蓝腾制药公司 使用隐陡头菌素或羟基脲甲基酰基富烯治疗脑转移瘤和cns转移瘤
CA3215236A1 (en) * 2021-04-12 2022-10-20 Aditya Kulkarni Method for treating lung cancer and non-small cell lung cancer
CN117320704A (zh) * 2021-05-03 2023-12-29 蓝腾制药公司 血癌的治疗方法
JP2024528725A (ja) * 2021-07-29 2024-07-30 ランタン ファルマ インコーポレイテッド Ｐａｒｐ阻害剤及びアシルフルベンの併用によるがんの治療
KR20240073856A (ko) * 2021-07-29 2024-05-27 랜턴 파마 인코포레이티드 스피로노락톤 및 아실풀벤의 조합을 이용한 암의 치료
CN121218981A (zh) * 2023-05-30 2025-12-26 蓝腾制药公司 用抗cd20抗体和酰基富烯的组合治疗癌症

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459157A (en) * 1891-09-08 Running-gear for vehicles
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4612302A (en) * 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
JPS62234040A (ja) 1986-04-02 1987-10-14 Kyowa Hakko Kogyo Co Ltd Ｄｃ１０４３物質
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH04502012A (ja) 1989-09-27 1992-04-09 モスコフスキ　ナウチノ―イススレドバテルスキ　インスティテュト　グラツィニフ　ボレツネイ　イメニ　ゲルムゴルツァ 進行性近視の治療用組成物
CA2067365C (en) * 1989-10-03 2006-01-31 Michael J. Kelner Illudin analogs as anti-tumor agents
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
HU208115B (en) * 1989-10-03 1993-08-30 Biochemie Gmbh New process for producting pleuromutilin derivatives
EP0450761A1 (en) * 1990-03-02 1991-10-09 Merck & Co. Inc. Spirocyclic oxytocin antagonists
KR900016822A (ko) * 1990-04-20 1990-11-14 하라 레이노스께 슬라이드 프로젝터
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
EP0699069B9 (en) 1993-04-27 2003-10-22 Smithkline Beecham Corporation Endothelin receptor antagonists
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
JP3908798B2 (ja) * 1994-09-12 2007-04-25 武田薬品工業株式会社 ベンゾシクロアルケン類、その製造法および剤
AU3399895A (en) * 1994-09-12 1996-03-29 Takeda Chemical Industries Ltd. Benzocycloalkene compounds, their production and use
US5932553A (en) * 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) * 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
US7141603B2 (en) * 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6025328A (en) * 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents

Also Published As

Publication number Publication date
US20080306147A1 (en) 2008-12-11
WO2007019308A2 (en) 2007-02-15
US7655695B2 (en) 2010-02-02
EP1909783A2 (en) 2008-04-16
WO2007019308A3 (en) 2007-07-12
EP1909783B1 (en) 2011-10-12
JP2009503110A (ja) 2009-01-29
JP4989648B2 (ja) 2012-08-01
EP1909783A4 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
ATE527998T1 (de) Illudin-analoga als krebsmittel
BRPI0608175A2 (pt) método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
IL180725A0 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
CU24269B1 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
MX349144B (es) Supresion de tumores utilizando perfundido placentario humano y celulas destructoras naturales intermediarias derivadas de la placenta humana.
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
CL2012001180A1 (es) Compuestos derrivados de pirrolo[2,3-b]piridina; inhibidores de cinasa-fms; metodo de preparacion de los compuestos; composicion y combinacion farmaceutica que los comprende; kit que incluye al compuesto o composicion; y uso en el tratamiento de enfermedades tales como tumores de celulas mamarias, cancer de prostata, alzheimer, entre otras.
PE20070723A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
TW200942552A (en) Combination therapy with c-Met and HER antagonists
SI1404811T1 (sl) Ogljikov monoksid izboljša rezultate pri presaditvi tkiva in organov ter prepreči apoptozo
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
IN2014DN08886A (https=)
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
EP1712235A3 (en) Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
WO2007048002A3 (en) Camptothecin derivatives as chemoradiosensitizing agents
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
MX2009001014A (es) Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
ECSP066457A (es) 5-arilpirimidinas como agentes anti-cancer
ECSP066458A (es) 6-[(sustituido)fenil]triazolopirimidinas como agentes anticancer
DE602005027739D1 (de) Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties